Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 81INDUSTRY 48NIH 10NETWORK 2OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Triple Negative Breast Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Breast Neoplasms 1

Interventions

peginterferon alfa-2a 1nilotinib 1Imatinib Mesylate 14-fluorobenzoyl-TN-14003 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Imatinib Mesylate × Clear all
NCT00297570 2007-10-10

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Sheba Medical Center

Phase 3 Unknown
90 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡